L‐glutamic acid as a neurotransmitter in the CNS

Marmo, E

doi:10.1002/med.2610080305

Cited by 14 publications

(2 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and is involved in the pathogenesis of acute and chronic neurological disorders, when its extracellular concentration rises to toxic levels (excitotoxicity) [7,14,36]. Clearance of the excessive neurotoxic concentrations of glutamate is ensured by a high affinity glutamate uptake system, present in neurons and glial cells [32,39].…”

Section: Introductionmentioning

confidence: 99%

Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer’s disease

Zoia

Cogliati

Tagliabue

et al. 2004

Neurobiology of Aging

View full text Add to dashboard Cite

Platelets release glutamate upon activation and are an important clearance system of the amino acid from blood, through high-affinity glutamate uptake, similar to that described in brain synaptosomes. Since platelet glutamate uptake is decreased in neurodegenerative disorders, we performed a morphological and molecular characterization of platelet glutamate transporters. The three major brain glutamate transporters EAAT1, EAAT2 and EAAT3 are expressed in platelets, with similar molecular weight, although at lower density than brain. A Na + -dependent-high-affinity glutamate uptake was competitively inhibited by known inhibitors but not by dihydrokainic acid, suggesting platelet EAAT2 does not play a major role in glutamate uptake at physiological conditions. We observed decreased glutamate uptake V max , without modification of transporter affinity, in aging, which could be linked to the selective decrease of EAAT1 expression and mRNA. Moreover, in AD patients we found a further EAAT1 reduction compared to age-matched controls, which could explain the decrease of platelet uptake previously described. Platelet glutamate transporters may be used as peripheral markers to investigate the role of glutamate in patients with neuropsychiatric disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer’s disease

Zoia

Cogliati

Tagliabue

et al. 2004

Neurobiology of Aging

View full text Add to dashboard Cite

show abstract

“…The prototypical competitive antagonists such as AP5 and AF7 [4] are straight chain w phosphono-a-amino acids. These compounds are very polar and suffer from poor brain penetration [lo], severely limiting their in vivo activity.…”

Section: Competitive Antagonistsmentioning

confidence: 99%